Vanguard Fiduciary Trust
TCRX icon

Vanguard Fiduciary Trust’s TScan Therapeutics TCRX Stock Holding History

Vanguard Fiduciary Trust’s Portfolio TCRX Stock Details TCRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$357K Buy
363,954
+58,182
+19% +$62K ﹤0.01% 3386
2026
Q1 		$309K Buy
+305,772
New +$327K ﹤0.01% 3372

Other funds holding TCRX

LCM
Lynx1 Capital Management San Juan, Puerto Rico $866M AUM 231.68% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
DMC
Deer Management Company Larchmont, New York $812M AUM 2.64% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Jacobs Levy Equity Management
Jacobs Levy Equity Management Florham Park, New Jersey $27.8B AUM 46.46% 1-Year Est. Return

Vanguard Fiduciary Trust's TCRX Position: Q2 2026 in Review

Vanguard Fiduciary Trust increased its TScan Therapeutics (TCRX) stake by 19% in Q2 2026, buying an estimated $62K and bringing the position to 363,954 shares worth $357K. The position accounts for ﹤0.01% of the portfolio, ranked #3386.

Vanguard Fiduciary Trust first reported a position in TCRX in Q1 2026 and has held it in 2 quarters since. 60 funds tracked by Wall St. Rank hold TCRX as of Q2 2026.

  • Vanguard Fiduciary Trust held 363,954 shares of TScan Therapeutics worth $357K as of Q2 2026.
  • Vanguard Fiduciary Trust bought 58,182 TScan Therapeutics shares in Q2 2026, an estimated $62K.
  • TScan Therapeutics made up ﹤0.01% of Vanguard Fiduciary Trust's portfolio in Q2 2026, its #3386 holding.
  • Vanguard Fiduciary Trust first reported a position in TScan Therapeutics in Q1 2026 and has held it in 2 quarters since.
  • 60 funds tracked by Wall St. Rank held TScan Therapeutics as of Q2 2026.

Based on Vanguard Fiduciary Trust's 13F filing for Q2 2026, filed 13 Aug 2026.